Analyst Sentiment Shifts as Hims & Hers Forges New Path with Pharma Giant

A significant strategic pivot by telehealth provider Hims & Hers has prompted a swift reassessment from Wall Street. The company has resolved a contentious legal dispute and fundamentally altered its business model, moving from selling controversial copycat drugs to becoming an authorized distributor for established pharmaceuticals. This shift has eliminated a major overhang on the stock and led several major financial institutions to revise their outlook.

From Legal Headwind to Strategic Partnership

The reassessment stems from a definitive agreement announced on March 9, 2026, with Danish pharmaceutical leader Novo Nordisk. This deal concludes a months-long, heated dispute. Previously, Hims & Hers had been marketing compounded medications—custom-mixed copies of popular GLP-1 weight-loss drugs—for $49. Novo Nordisk responded in February with a lawsuit alleging mass illegal manufacturing, prompting involvement from the U.S. Food and Drug Administration, which referred the case to the Department of Justice.

Under the new partnership, the strategy is transformed. Hims & Hers will cease promotion of unapproved copycat formulations. Instead, its U.S. platform will offer genuine Novo Nordisk medications, Ozempic and Wegovy, at standard market prices. The use of compounded versions will be reserved only for exceptional medical circumstances where necessary.

Financial Institutions Revise Targets

This resolution has triggered a wave of updated analyst commentary, with multiple firms raising their price objectives for the telehealth company’s equity:

Should investors sell immediately? Or is it worth buying Hims & Hers?

• Barclays lifted its target to $29 from $25, maintaining an “Overweight” rating.
• Deutsche Bank increased its price objective to $28 from $25, with a “Hold” recommendation.
• Leerink Partners raised its target to $25 from $17.50, rating the shares “Market Perform.”
• Bank of America upgraded its stance from “Underperform” to “Neutral,” nearly doubling its price target to $23.

These adjustments reflect a materially improved risk profile, as the agreement removes the largest legal uncertainty that had been pressuring the share price.

A Strong Foundation for Transition

The company is navigating this strategic shift from a position of operational strength. Its fourth-quarter financial performance exceeded market expectations, with revenue reaching nearly $618 million. On a per-share basis, earnings came in at $0.08, significantly above the estimated $0.02. The subscriber base also showed robust growth, increasing by 13% year-over-year to surpass 2.5 million users.

The immediate challenge for management is the operational execution of this transition. Hims & Hers must now migrate its existing base of 418,000 GLP-1 customers to the approved brand-name medications. Market observers will closely monitor the coming quarters to see if the profit margins from distributing Novo Nordisk’s original products are sufficient to sustain the telehealth provider’s historical revenue growth trajectory.